Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 51
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
Rev Med Suisse ; 20(872): 881-885, 2024 May 01.
Artículo en Francés | MEDLINE | ID: mdl-38693801

RESUMEN

Marburg virus disease (MVD) is a dreadful but exceptional disease. Formerly mainly identified in Uganda, Angola and the Democratic Republic of Congo, it has recently appeared in the Republic of Guinea, Ghana, Equatorial Guinea and Tanzania, adding West Africa to the affected regions. Humans become infected through exposure to bats Roussettus aegyptiacus or during unprotected care of infected people. Five cases are linked to travellers, the last one dates to 2008 and involved a visit to caves colonized by bats. At present, there is no specific treatment or vaccine. Despite its rarity, adventurous travelers should be aware of the risks of exposure and avoid entering places inhabited by bats.


La maladie à virus Marburg est une maladie redoutable mais exceptionnelle. Autrefois identifiée en Ouganda, Angola et République démocratique du Congo, elle a récemment fait son apparition en République de Guinée, au Ghana, en Guinée équatoriale et en Tanzanie, ajoutant l'Afrique de l'Ouest aux régions touchées. Les humains s'infectent lors d'une exposition avec les chauves-souris roussettes d'Égypte ou lors de la prise en charge sans protection de personnes infectées. Cinq cas sont liés à des voyageurs, le dernier remonte à 2008 et était associé à la visite de grottes colonisées par des roussettes d'Égypte. Actuellement, il n'existe aucun traitement spécifique ni vaccin. Malgré sa rareté, les voyageurs aventureux doivent être informés des risques d'exposition et éviter de pénétrer dans des lieux habités par des chauves-souris.


Asunto(s)
Marburgvirus , Viaje , Femenino , Humanos , Masculino , Enfermedad del Virus de Marburg/epidemiología , Enfermedad del Virus de Marburg/transmisión , Enfermedad del Virus de Marburg/virología , Marburgvirus/aislamiento & purificación , Zoonosis Virales/epidemiología , Zoonosis Virales/transmisión , Zoonosis Virales/virología , Quirópteros/virología
2.
Clin Infect Dis ; 77(1): 135-137, 2023 07 05.
Artículo en Inglés | MEDLINE | ID: mdl-36905148

RESUMEN

A healthy young man first diagnosed with mpox in May 2022 presented again in November 2022 with anal proctitis and a positive polymerase chain reaction on a rectal swab for Monkeypox virus after a recent trip to Brazil, where he engaged in condomless sexual intercourse with multiple male partners.


Asunto(s)
Mpox , Humanos , Masculino , Reinfección , Brasil , Monkeypox virus , Reacción en Cadena de la Polimerasa
3.
Rev Med Suisse ; 19(825): 858-864, 2023 May 03.
Artículo en Francés | MEDLINE | ID: mdl-37139881

RESUMEN

In 2022, mpox - a neglected tropical zoonosis - emerged to the world stage. From 1980, the disease was periodically noted, with increasing frequency, in endemic regions of Africa. In 2017, a large outbreak in Nigeria marks a turning point in the evolution of mpox and seems to be at the origin of the 2022 pandemic. The factors for mpox emergence are complex and include loss of cross-protection conferred by smallpox vaccination, increased exposure to the animal reservoir, and increased human-to-human transmission due to behavioral factors. While the current epidemic seems under control, an evolution towards a more transmissible or more virulent virus is not excluded. The 2022 pandemic is an opportunity to initiate and strengthen mpox surveillance, prevention and care management among all affected populations.


En 2022, le mpox ­ une zoonose tropicale négligée ­ a émergé sur la scène mondiale. Depuis 1980, la maladie a été notifiée avec une fréquence croissante dans les régions endémiques d'Afrique. En 2017, une large épidémie au Nigeria marque un tournant dans l'évolution du mpox et semble à l'origine de la pandémie 2022. Les facteurs d'émergence du mpox sont complexes et incluent la perte de la protection croisée conférée par la vaccination antivariolique, une exposition accrue au réservoir animal et une augmentation de la transmission interhumaine due à des facteurs comportementaux. Alors que l'épidémie actuelle semble sous contrôle, une évolution vers un virus plus transmissible ou plus virulent n'est pas exclue. La pandémie 2022 est une opportunité pour initier et renforcer la surveillance, la prévention et la prise en charge clinique du mpox auprès de toutes les populations affectées.


Asunto(s)
Mpox , Viruela , Animales , Humanos , Viruela/epidemiología , Viruela/prevención & control , Mpox/diagnóstico , Mpox/epidemiología , Mpox/prevención & control , Zoonosis/epidemiología , Zoonosis/prevención & control , África , Pandemias
5.
J Intern Med ; 292(1): 103-115, 2022 07.
Artículo en Inglés | MEDLINE | ID: mdl-35555926

RESUMEN

BACKGROUND: Persistent symptoms of SARS-CoV-2 are prevalent weeks to months following the infection. To date, it is difficult to disentangle the direct from the indirect effects of SARS-CoV-2, including lockdown, social, and economic factors. OBJECTIVE: The study aims to characterize the prevalence of symptoms, functional capacity, and quality of life at 12 months in outpatient symptomatic individuals tested positive for SARS-CoV-2 compared to individuals tested negative. METHODS: From 23 April to 27 July 2021, outpatient symptomatic individuals tested for SARS-CoV-2 at the Geneva University Hospitals were followed up 12 months after their test date. RESULTS: At 12 months, out of the 1447 participants (mean age 45.2 years, 61.2% women), 33.4% reported residual mild to moderate symptoms following SARS-CoV-2 infection compared to 6.5% in the control group. Symptoms included fatigue (16% vs. 3.1%), dyspnea (8.9% vs. 1.1%), headache (9.8% vs. 1.7%), insomnia (8.9% vs. 2.7%), and difficulty concentrating (7.4% vs. 2.5%). When compared to the control group, 30.5% of SARS-CoV-2 positive individuals reported functional impairment at 12 months versus 6.6%. SARS-CoV-2 infection was associated with the persistence of symptoms (adjusted odds ratio [aOR] 4.1; 2.60-6.83) and functional impairment (aOR 3.54; 2.16-5.80) overall, and in subgroups of women, men, individuals younger than 40 years, those between 40-59 years, and in individuals with no past medical or psychiatric history. CONCLUSION: SARS-CoV-2 infection leads to persistent symptoms over several months, including in young healthy individuals, in addition to the pandemic effects, and potentially more than other common respiratory infections. Symptoms impact functional capacity up to 12 months post infection.


Asunto(s)
COVID-19 , SARS-CoV-2 , COVID-19/epidemiología , Control de Enfermedades Transmisibles , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pandemias , Calidad de Vida
6.
Clin Infect Dis ; 73(1): 148-150, 2021 07 01.
Artículo en Inglés | MEDLINE | ID: mdl-32761228

RESUMEN

The factors that contribute to transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by children are unclear. We analyzed viral load at the time of diagnosis in 53 children and 352 adults with coronavirus disease 2019 (COVID-19) in the first 5 days post symptom onset. No significant differences in SARS-CoV-2 RNA loads were seen between children and adults.


Asunto(s)
COVID-19 , SARS-CoV-2 , Adulto , Niño , Humanos , ARN Viral , Sistema Respiratorio , Carga Viral
7.
Prev Med ; 150: 106696, 2021 09.
Artículo en Inglés | MEDLINE | ID: mdl-34174252

RESUMEN

During the first wave of the Covid-19 pandemic, access to health care was limited, and patients encountered important delays for scheduled appointments and care. Empirical data relying on patients' reports of forgoing health care are scarce. This study investigated Covid-19-related self-reports of forgoing health care in a sample of vulnerable outpatients in Geneva, Switzerland. We collected data from 1167 adult outpatients, including clinically vulnerable patients (with chronic diseases), geriatric patients (involved in a health care network for people aged 60 or older), and socially vulnerable patients (involved in a migrant health program or a mobile outpatient community care center) in June 2020. Data on sociodemographic factors, forgoing health care, and anti-SARS-CoV-2 antibodies were collected. Of the patients, 38.5% reported forgoing health care. Forgoing health care was more frequent for younger patients, women, patients with a low level of education, and patients with a chronic disease (p < .001). There was no significant association between the presence of anti-SARS-CoV-2 antibodies and forgoing health care (p = .983). As the decrease in routine management of patients might have important and unpredictable adverse health consequences, avoiding delayed health care is crucial.


Asunto(s)
COVID-19 , Pandemias , Adulto , Anciano , Atención a la Salud , Femenino , Humanos , SARS-CoV-2 , Suiza
8.
Rev Med Suisse ; 17(737): 866-870, 2021 May 05.
Artículo en Francés | MEDLINE | ID: mdl-33950587

RESUMEN

Before a trip, a screening for SARS-CoV-2 infection by RT-PCR is often required and raises the problem of detection of residual viral RNA at distance from the acute infection (post-Covid). At the University Hospital of Geneva, we developed an expertise to distinguish acute from post-Covid infections. Between October and December 2020, 30% of the people tested positive were able to travel because the result corresponded to post-Covid and 65% were put in isolation because of an acute infection with a risk of transmission. To overcome the detection of residual viral RNA by RT-PCR, a rapid antigenic test would be an interesting and less expensive alternative. It could also be performed a few hours before departure.


Avant un voyage, un dépistage de l'infection à SARS-CoV-2 par RT-PCR est souvent exigé et soulève le problème de la détection d'ARN viral résiduel chez une personne à distance de l'infection aiguë (post-Covid). Aux HUG, nous avons développé une expertise permettant de distinguer les infections aiguës des post-Covid. Entre octobre et décembre 2020, 30 % des personnes dépistées positives ont pu voyager car le résultat correspondait à des post-Covid et 65 % ont été mises en isolement en raison d'une infection aiguë avec risque de transmission. Pour pallier la détection de l'ARN viral résiduel par la RT-PCR, un test rapide antigénique serait une alternative intéressante et moins chère. Il pourrait également être effectué juste avant le départ.


Asunto(s)
COVID-19 , SARS-CoV-2 , Humanos , Tamizaje Masivo , Viaje
9.
Rev Med Suisse ; 17(720-1): 42-49, 2021 Jan 13.
Artículo en Francés | MEDLINE | ID: mdl-33443830

RESUMEN

What's new in infectious diseases in 2020 ? This year has been marked by the COVID-19 pandemic, prompting a review of the current knowledge on SARS-CoV-2 and its management in this article. The results of the Swiss project «â€…PIRATE ¼ indicate non-inferiority between CRP-guided antibiotic durations or fixed 7-day durations and 14-day durations for Gram-negative bacteremia. A Mongolian study did not show any benefit of vitamin D substitution in protecting children from tuberculosis. Baloxavir, a new antiviral against the flu, has been approved by Swissmedic. Finally, new American recommendations for therapeutic monitoring of vancomycin and universal screening for hepatitis C virus have been published.


Que dire des nouveautés en maladies infectieuses en 2020 ? L'année a été marquée évidemment par la pandémie du Covid-19, motivant une revue dans cet article, des connaissances actuelles sur le SARS-CoV-2 et de sa prise en charge. Les résultats du projet suisse PIRATE ont montré une non-infériorité pour les bactériémies Gram négatif entre une antibiothérapie de 7 jours ou guidée par la CRP face à une durée de 14 jours. Une étude mongolienne n'a pas permis de montrer le bénéfice d'une substitution en vitamine D chez les enfants sur l'incidence de la tuberculose. Le baloxavir, un nouvel antiviral contre la grippe, a été approuvé par Swissmedic. Et enfin, des nouvelles recommandations américaines sur le monitoring thérapeutique de la vancomycine et sur le dépistage universel de l'hépatite C ont été publiées.


Asunto(s)
Infectología/tendencias , Antibacterianos/administración & dosificación , Antivirales/uso terapéutico , Proteína C-Reactiva/análisis , COVID-19 , Niño , Enfermedades Transmisibles/tratamiento farmacológico , Humanos , Gripe Humana/tratamiento farmacológico , Pandemias , Tuberculosis/prevención & control , Vitamina D/administración & dosificación
13.
Rev Med Suisse ; 15(664): 1694-1698, 2019 Sep 25.
Artículo en Francés | MEDLINE | ID: mdl-31553532

RESUMEN

Narrative overviews of scientific literature contribute to the updating and critique of available medical knowledge. Indirectly, they help to formulate new research projects based on the synthesis and interpretation of the results of a non-systematic selection of published studies. To facilitate both optimal reading and synthesis of studies we deem useful to propose a standardized approach to the various steps of the development and writing of a narrative literature overview.


Les revues de littérature scientifique de type narratif contribuent à la mise à jour et à la critique des connaissances médicales. Indirectement, elles aident à l'élaboration de nouveaux projets de recherche basés sur la synthèse et l'interprétation des résultats d'une sélection non systématique de publications scientifiques. Afin d'en optimiser la lecture et la synthèse, il nous paraît utile de proposer une méthode standardisée des différentes étapes de préparation et de rédaction d'une revue de littérature de type narratif.


Asunto(s)
Narración , Literatura de Revisión como Asunto , Escritura/normas
14.
N Engl J Med ; 372(1): 40-7, 2015 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-25372658

RESUMEN

BACKGROUND: In March 2014, the World Health Organization was notified of an outbreak of Zaire ebolavirus in a remote area of Guinea. The outbreak then spread to the capital, Conakry, and to neighboring countries and has subsequently become the largest epidemic of Ebola virus disease (EVD) to date. METHODS: From March 25 to April 26, 2014, we performed a study of all patients with laboratory-confirmed EVD in Conakry. Mortality was the primary outcome. Secondary outcomes included patient characteristics, complications, treatments, and comparisons between survivors and nonsurvivors. RESULTS: Of 80 patients who presented with symptoms, 37 had laboratory-confirmed EVD. Among confirmed cases, the median age was 38 years (interquartile range, 28 to 46), 24 patients (65%) were men, and 14 (38%) were health care workers; among the health care workers, nosocomial transmission was implicated in 12 patients (32%). Patients with confirmed EVD presented to the hospital a median of 5 days (interquartile range, 3 to 7) after the onset of symptoms, most commonly with fever (in 84% of the patients; mean temperature, 38.6°C), fatigue (in 65%), diarrhea (in 62%), and tachycardia (mean heart rate, >93 beats per minute). Of these patients, 28 (76%) were treated with intravenous fluids and 37 (100%) with antibiotics. Sixteen patients (43%) died, with a median time from symptom onset to death of 8 days (interquartile range, 7 to 11). Patients who were 40 years of age or older, as compared with those under the age of 40 years, had a relative risk of death of 3.49 (95% confidence interval, 1.42 to 8.59; P=0.007). CONCLUSIONS: Patients with EVD presented with evidence of dehydration associated with vomiting and severe diarrhea. Despite attempts at volume repletion, antimicrobial therapy, and limited laboratory services, the rate of death was 43%.


Asunto(s)
Deshidratación/etiología , Fiebre Hemorrágica Ebola/complicaciones , Fiebre Hemorrágica Ebola/mortalidad , Adulto , Factores de Edad , Antiinfecciosos/uso terapéutico , Diarrea/etiología , Ebolavirus , Epidemias , Femenino , Fiebre/etiología , Fluidoterapia , Guinea/epidemiología , Fiebre Hemorrágica Ebola/epidemiología , Humanos , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Riesgo , Tasa de Supervivencia , Taquicardia/etiología , Vómitos/etiología
16.
20.
Am J Respir Crit Care Med ; 190(7): 733-7, 2014 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-25166884

RESUMEN

The largest ever Ebola virus disease outbreak is ravaging West Africa. The constellation of little public health infrastructure, low levels of health literacy, limited acute care and infection prevention and control resources, densely populated areas, and a highly transmissible and lethal viral infection have led to thousands of confirmed, probable, or suspected cases thus far. Ebola virus disease is characterized by a febrile severe illness with profound gastrointestinal manifestations and is complicated by intravascular volume depletion, shock, profound electrolyte abnormalities, and organ dysfunction. Despite no proven Ebola virus-specific medical therapies, the potential effect of supportive care is great for a condition with high baseline mortality and one usually occurring in resource-constrained settings. With more personnel, basic monitoring, and supportive treatment, many of the sickest patients with Ebola virus disease do not need to die. Ebola virus disease represents an illness ready for a paradigm shift in care delivery and outcomes, and the profession of critical care medicine can and should be instrumental in helping this happen.


Asunto(s)
Cuidados Críticos/métodos , Fiebre Hemorrágica Ebola/terapia , Atención al Paciente/métodos , África Occidental/epidemiología , Enfermedad Crítica , Brotes de Enfermedades/estadística & datos numéricos , Fiebre Hemorrágica Ebola/epidemiología , Humanos , Cuidados Paliativos/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA